Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01986348
Title Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide
Acronym KING
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Karyopharm Therapeutics, Inc
Age Groups: adult
Covered Countries USA | NLD

Facility Status City State Zip Country Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute, Center for Neuro-Oncology Boston Massachusetts 02215 United States Details
Columbia University, Herbert Irving Comprehensive Cancer Center New York New York 10032 United States Details
The Phase I Unit, Dept. of Oncology, Rigshospitalet Copenhagen DK-2100 Denmark Details
University of Groningen Faculty of Medical Sciences, Medical Oncology Groningen 9713 GZ Netherlands Details
Erasmus MC-Daniel den Hoed Cancer Center- Neuro-Oncology Unit Rotterdam 3008AE Netherlands Details
*Shaded cells indicate that there was no data available from for the field